nach oben

International Journal of Clinical Oncology

Erschienen in:

11.09.2024 | Special Article

Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology

verfasst von: Toshinobu Hayashi, Shun Yamamoto, Yoshiharu Miyata, Masayuki Takeda, Masakazu Abe, Makoto Wada, Keiko Iino, Tatsuo Akechi, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-Il Kim, Hidenori Sasaki, Eriko Satomi, Ryuhei Tanaka, Takako Eguchi Nakajima, Naoki Nakamura, Junichi Nishimura, Mayumi Noda, Kazumi Hayashi, Takahiro Higashi, Narikazu Boku, Koji Matsumoto, Yoko Matsumoto, Kenji Okita, Nobuyuki Yamamoto, Kenjiro Aogi, Hirotoshi Iihara

Erschienen in: International Journal of Clinical Oncology | Ausgabe 11/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Chemotherapy-induced nausea and vomiting (CINV) commonly affects patient quality of life and the overall effectiveness of chemotherapy. This study aimed to evaluate whether adding neurokinin-1 receptor antagonists (NK1RAs) to 5-hydroxytryptamine-3 receptor antagonists (5-HT₃RAs) and corticosteroids provides clinically meaningful benefits in preventing CINV in patients receiving moderately emetogenic chemotherapy (MEC).

Methods

We conducted a systematic review of PubMed, Cochrane Library, and Ichushi-Web to identify clinical studies evaluating NK1RAs combined with 5-HT₃RAs and dexamethasone for managing CINV in MEC. The endpoints were complete response (CR), complete control (CC), total control (TC), adverse events, and costs. The data were analyzed using a random effects model.

Results

From 142 articles identified, 15 randomized controlled trials (RCTs), involving 4,405 patients, were included in the meta-analysis. Approximately 60% of the patients received carboplatin (CBDCA)-based chemotherapy. The meta-analysis showed that triplet antiemetic prophylaxis with NK1RA was significantly more effective for achieving CR than doublet prophylaxis in each phase. Regarding CC, the triplet antiemetic prophylaxis was significantly more effective than the doublet in the overall (risk difference [RD]: 0.11, 95% confidence interval [CI]: 0.06–0.17) and delayed (RD: 0.08, 95% CI: 0.02–0.13) phases. For TC, no significant differences were observed in any phase. Adding NK1RA did not cause adverse events.

Conclusions

Adding NK1RA to CBDCA-based chemotherapy has shown clinical benefits. However, the clinical benefits of NK1RA-containing regimens for overall MEC have not yet been established and require RCTs that exclusively evaluate MEC regimens other than CBDCA-based chemotherapy.

Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782–2797. https://doi.org/10.1200/JCO.20.01296CrossRefPubMed

Herrstedt J, Clark-Snow R, Ruhlmann CH et al (2024) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 9:102195. https://doi.org/10.1016/j.esmoop.2023.102195CrossRefPubMed

NCCN (2024) NCCN clinical practice guidelines in oncology. Antiemetics, version 1. Accessed 5 Jan 2024

Iihara H, Abe M, Wada M et al (2024) 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol 29:873–888. https://doi.org/10.1007/s10147-024-02535-xCrossRefPubMed

Jordan K, Blättermann L, Hinke A et al (2018) Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis. Support Care Cancer 26:21–32. https://doi.org/10.1007/s00520-017-3857-7CrossRefPubMed

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29(372):n71. https://doi.org/10.1136/bmj.n71CrossRef

Minds Manual Developing Committee ed. (2016) Minds manual for guideline development 2017. Japan Council for Quality Health Care, Tokyo

Arpornwirat W, Albert I, Hansen VL et al (2009) Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer 115:5807–5816. https://doi.org/10.1002/cncr.24630CrossRefPubMed

Rapoport BL, Jordan K, Boice JA et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423–431. https://doi.org/10.1007/s00520-009-0680-9CrossRefPubMed

10.

Tanioka M, Kitao A, Matsumoto K et al (2013) A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 109:859–865. https://doi.org/10.1038/bjc.2013.400CrossRefPubMed

11.

Kitayama H, Tsuji Y, Sugiyama J et al (2015) Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study. Int J Clin Oncol 20:1051–1056. https://doi.org/10.1007/s10147-015-0823-6CrossRefPubMed

12.

Kusagaya H, Inui N, Karayama M et al (2015) Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer 90:410–416. https://doi.org/10.1016/j.lungcan.2015.11.009CrossRefPubMed

13.

Maehara M, Ueda T, Miyahara D et al (2015) Clinical efficacy of aprepitant in patients with gynecological cancer after chemotherapy using paclitaxel and carboplatin. Anticancer Res 35:4527–4534PubMed

14.

Nishimura J, Satoh T, Fukunaga M et al (2015) Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51:1274–1282. https://doi.org/10.1016/j.ejca.2015.03.024CrossRefPubMed

15.

Schwartzberg LS, Modiano MR, Rapoport BL et al (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 16:1071–1078. https://doi.org/10.1016/S1470-2045(15)00034-0CrossRefPubMed

16.

Kaushal P, Atri R, Soni A et al (2015) Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients. Ecancermedicalscience 9:567. https://doi.org/10.3332/ecancer.2015.567CrossRefPubMed

17.

Weinstein C, Jordan K, Green SA et al (2016) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol 27:172–178. https://doi.org/10.1093/annonc/mdv482CrossRefPubMed

18.

Yahata H, Kobayashi H, Sonoda K et al (2016) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 21:491–497. https://doi.org/10.1007/s10147-015-0928-yCrossRefPubMed

19.

Aridome K, Mori SI, Baba K et al (2016) A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients. Mol Clin Oncol 4:393–398. https://doi.org/10.3892/mco.2015.724CrossRefPubMed

20.

Hesketh PJ, Schnadig ID, Schwartzberg LS et al (2016) Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer 122:2418–2425. https://doi.org/10.1002/cncr.30054CrossRefPubMed

21.

Kim JE, Jang JS, Kim JW et al (2017) Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Support Care Cancer 25:801–809. https://doi.org/10.1007/s00520-016-3463-0CrossRefPubMed

22.

Sugimori Y, Ota T, Ujihira T et al (2017) A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer. J Obstet Gynaecol Res 43:1454–1459. https://doi.org/10.1111/jog.13378CrossRefPubMed

23.

Tsukiyama I, Ando M, Tsukiyama S et al (2019) Cost-utility analysis of aprepitant for patients who truly need it in Japan. Support Care Cancer 27:3749–3758. https://doi.org/10.1007/s00520-019-04672-wCrossRefPubMed

24.

Aapro M, Carides A, Rapoport BL et al (2015) Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist 20:450–458. https://doi.org/10.1634/theoncologist.2014-0229CrossRefPubMedPubMedCentral

25.

Bošnjak SM, Gralla RJ, Schwartzberg L (2017) Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists. Support Care Cancer 25:1661–1671. https://doi.org/10.1007/s00520-017-3585-zCrossRefPubMedPubMedCentral

26.

Tamura K, Aiba K, Saeki T et al (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV study group of Japan. Int J Clin Oncol 20:855–865. https://doi.org/10.1007/s10147-015-0786-7CrossRefPubMed

27.

Iihara H, Shimokawa M, Hayashi T et al (2020) A nationwide, multicenter registry study of antiemesis for carboplatin-based chemotherapy-induced nausea and vomiting in Japan. Oncologist 25:e373–e380. https://doi.org/10.1634/theoncologist.2019-0292CrossRefPubMed

Titel: Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology
verfasst von: Toshinobu Hayashi
Shun Yamamoto
Yoshiharu Miyata
Masayuki Takeda
Masakazu Abe
Makoto Wada
Keiko Iino
Tatsuo Akechi
Chiyo K. Imamura
Ayako Okuyama
Keiko Ozawa
Yong-Il Kim
Hidenori Sasaki
Eriko Satomi
Ryuhei Tanaka
Takako Eguchi Nakajima
Naoki Nakamura
Junichi Nishimura
Mayumi Noda
Kazumi Hayashi
Takahiro Higashi
Narikazu Boku
Koji Matsumoto
Yoko Matsumoto
Kenji Okita
Nobuyuki Yamamoto
Kenjiro Aogi
Hirotoshi Iihara
Publikationsdatum: 11.09.2024
Verlag: Springer Nature Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 11/2024
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-024-02623-y

Prognosis of early-onset vs. late-onset stage II/III colorectal cancer patients with adjuvant chemotherapy: a multicenter propensity score matched study

Original Article

Changes in outcome of patients with advanced non-clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno-oncology era

Original Article

Current status and prospects of breast cancer imaging-based diagnosis using artificial intelligence

Invited Review Article

Current status and prospects of artificial intelligence in breast cancer pathology: convolutional neural networks to prospective Vision Transformers

Invited Review Article

Predicting invasive disease-free survival in ER-positive, HER2-negative early breast cancer using the PAM50 risk-of-recurrence score: a retrospective analysis using single-center long-term follow-up data of postmenopausal Japanese patients

Open Access
Original Article

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of alectinib and pembrolizumab for the adjuvant treatment of non-small cell lung cancer in Japan

PMDA Regulatory Update

Neu im Fachgebiet Onkologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

16.01.2025
Zöliakie
Nachrichten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

15.01.2025
Melanom
Nachrichten

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin